Treatment of Osteoporotic Compression Fractures

C. Lan Fotopoulos, MD Interventional Physiatric Spine and Sports Kansas City Orthopaedic Alliance

Osteoporosis

- 54 million men and women have osteoporosis
- 2,000,000 men have osteoporosis
- 34,000,000 have osteopenia
- 1 in 2 white women and 1 in 4 men will experience an osteoporotic fracture in her lifetime.

Osteoporosis

Osteoporotic fractures cost \$18 billion annually
Projected to cost \$50 billion by 2040
Projected costs exceed the cost of stroke, breast CA, DM, or chronic lung disease

Definitions

- Osteoporosis-Characterized by low bone mass leading to an increased fracture risk
 WHO defines a bone mineral density (BMD)2.5 standard deviations below the mean for healthy
 - young women measured by dual energy x-ray absorptiometry (DEXA).
- Osteopenia-defined as BMD between 1-2.5 standard deviations below the mean.

Primary Osteoporosis

 Primary Osteoporosis – bone loss related to the decline of gonadal function associated with aging.

Increasing age

- Low body weight
- White or Asian
- Excessive alcohol and caffeine
- Low calcium and/or vitamin D intake

Secondary Osteoporosis

 Low bone mass resulting from chronic disease, exposures, or nutritional deficiencies. Amyloidosis

Ankylosing SpondylitisHIV

IBD

Severe Liver Diease

Renal Faliure

Rheumatoid Arthritis

SLE

Endocrine and Metabolic disorders

- Athletic amenorrhea
 - Disordered Eating, Amenorrhea, Osteoporosis
- Cushing Syndrome
- DM type 1
- Hemochromatosis
- Hyperadrenocorticism
- Primary hyperparathyroidism
- Hyperthyroidism
- Hypogonadism
- Hypophosphatasia

Medications

- Anticonvulsants
- Drugs causing hypogonadism
 Progesterone, methotrexate, GRHA
- Glucocorticoids
- Heparin
- Immunosuppessants
 - Cyclosporine,tacrolimus
- Lithium
- Thyroid Hormone Excess








VCF Treatment Options vs Non-Surgical Management

- Non-surgical treatment options
 - Bed rest
 - Physical therapy
 - Bracing
 - Opioids

Non-surgical management may lead to adverse outcomes that, if left untreated, may begin a "downwardspiral" in the health status of patients



Bracing





VCF Treatment vs Non-Surgical Management


Significantly higher mortality risk with NSM vs BKP/VP	N-value	Years of follow-up	Key findings
Ong et al. * (Osteo Int 2018) ³	2,077,944 BKP (n=261,756) VP (n=117,232) NSM (n=1,698,956)	10+	NSM: 55% and 24% higher mortality risk at 1 year and 10 years than BKP (Propensity adjusted: 95% CI: 23-24%; p<0.001). NSM: 30% and 8% higher mortality risk at 1 year and 10 years than VP. (Propensity adjusted: 95% CI: 8%-9%; p<0.001).
Edidin et al.* (Spine 2015)4	1,038,956 BKP (n = 41,343) VP (n = 75,364) NSM (n = 822,249)	4+	NSM: 55% higher mortality risk than BKP (AHR =1.55; 95% CI: 1.53–1.56) and 25% higher mortality risk than VP. After propensity matching, the Kaplan-Meier risk of mortality at 4 years was still found to be greater for the nonoperated cohort (AHR = 1.62; 95% CI: 1.60–1.64).
Edidin et al.* (JBMR 2011) ⁵ ✓	858,978 BKP (n = 119,253) VP (n = 63,693) NSM (n = 676,032)	4+	BKP: 44% lower mortality risk than NSM (AHR = 0.56, 95% CI 0.55–0.57). VP: 24% lower mortality risk than NSM.
Chen et al.* (JBJS 2013) ⁶	68,752 BKP (n = 22,826) VP (n = 7,700) NSM (n = 38,226)	3+	BKP: 32.5% lower mortality risk than NSM. VP: 15.5% lower mortality risk than NSM.
Lange et al.* (Spine 2014) ⁷	3,607 BKP (n = 441) VP (n = 157) NSM (n = 3,009)	5++	VP/BKP: 43% lower mortality risk than NSM (AHR = 0.57; 95% CI: 0.48–0.70).

Imaging

X-rays – Allows for quick screening and identification of fractures CT – Allows for best imaging of bony anatomy MRI – Optimal imaging for judging fracture age, as it shows bony edema for an acute fracture Bone scan – Less commonly used imaging, but will show increased uptake in a fracture and may be done in conjunction with a DEXA scan

Imaging

MRI with short T1-T2 inversion recovery (STIR)¹⁰



Imaging

Bone scan³ Allows for quick fracture evaluation from T4 to L4



CT scan³ Demonstrates fracture though posterior wall of vertebra



Number Needed to Treat with Vertebral Augmentation to Save a Life

American Journal of Neuroradiology January 2020, 41 (1) 178-182; DOI: https://doi.org/10.3174/ajnr.A6367

- Why Treat: Number Needed to Treat with VertebralAugmentation to Save a Life
- The purpose of this study was to calculate the number needed to treat (NNT) to save 1 life at 1 year and up to 5 years after vertebral augmentation.
- Pooled data from 10-year sample of US Medicare patients with vertebral compression fractures (VCFs) treated with nonsurgical management, balloon kyphoplasty, and vertebroplasty.
- Adjusted number needed to save 1 life saved for nonsurgical management versus kyphoplasty 14.8 at 1 year, 11.9 at 5 years; non-surgical management versus vertebroplasty ranged from 22.8 at 1 year, to 23.8 at 5 years.
- This large dataset analysis (>2 million patients) reveals that vertebral augmentation provides a significant mortality benefit over non-surgical management.

Vertebral Compression Fracture

- Osteoporosis
- Neoplasm
- Hemangioma
- Myeloma
- Metastasis



Osteoplasty

- A procedure for treatment of compression fractures.
- Promotes quicker return to activity.
- Originally not intended for treatment of traumatic fractures.

Originally not intended for treatment in those less than 55 years of age.

Kyphoplasty and Vertebroplasty

Vertebroplasty





Vertebroplasty





Vertebroplasty





New VCF treatment options

Bi-Pedicular Balloon Augmentation

Uni-Pedicular Balloon Augmentation


Spinejack Augmentation








Kyphoplasty



Kyphoplasty



Needle to posterior 1/3rd



Inflate balloon



Drill to anterior 1/3rd



Inject cement




Insert balloon




Cement interdigitates

The Procedure



Pre-kyphoplasty



- Minimally invasive (only 0.5 cm incision)
- General or local anesthesia
- Typically 15-20 minutes per treated fracture
- Adverse event risk due to bone cement leak very low (< 0.3% per patient)

IBT Inflation


Spine Jack




Spine Jack in action




Spinejack Difference




Pre-operative situation: ■ Patient: 62, Female Fracture type: Inferior Endplate Level: L4 ■ Pre-op VAS: 10/10 Post-operative situation: ■ 5.8mm Spinejack Cement amount: 4-6 cc ■ Post-op VAS: 1/10



Pre-operative situation: ■ Patient: 68 male ■ Fracture type: ■ 70% Compression Level: L1 ■ Pre-op VAS: 9/10 Post-operative situation: ■ 5.0mmSpinejack ■ Cement amount: 7-8 cc ■ Post-op VAS: 2/10



Pre-operative situation: ■ Patient: 61 male ■ Fracture type: 10% Compression Focus on less cement Level: L2 ■ Pre-op VAS: 10/10 Post-operative situation: ■ 5.0mmSpinejack Cement amount: 3-4 cc ■ Post-op VAS: 2/10



T-8


T-9

T-10

Pre-operative situation: ■ Patient: 73 female Fracture type: 40% Compression Level: T9 ■ Pre-op VAS: 10/10 Post-operative situation: 4.2mm Spinejack Cement amount: 5 cc ■ Post-op VAS: 3/10

Pre-operative situation: ■ Patient: 66 Female Levels: T10 & T11 ■ Pre-op VAS: 9/10 Post-operative situation: 4.2mm Spinejack T10 & T11 ■ Cement amount: 10cc Total ■ Post-op VAS: 2/10





Spine Jack

Correction of endplate deformity may help reduce the risk of adjacent level fractures

- In a study conducted by Edidin et al within a U.S. Medicare population from 2005-2009, VCF patients who received VA therapies experienced lower mortality and overall morbidity than VCF patients who received conservative management
- Significant pain relief
- Functional improvements
- Restoration of sagittal alignment

Spinejack Additional Benefits

- Greater midline VB height restoration
- Significantly fewer adjacent level fractures than kyphoplasty
- Results maintained over time in three-year follow-up
- Fast and sustainable improvement in quality of life
- Fracture reduction with ligamentotaxis leads to indirect central canal decompression

SAKOS Clinical Study

Mechanical vertebral augmentation SAKOS clinical study¹³

5 countries | 13 sites | 15 investigators

- Prospective, multicenter, randomized, comparative study
- N=141 (SpineJack system n=68; KyphX Xpander BKP n=73)
- Non-inferiority study
- 12-month follow up

Superior mid-vertebral height restoration

 Significantly greater midline VB height restoration with SJ system at 6 and 12 months

6 mo. p= 0.0246 12 mo. p= 0.0035

Significantly fewer adjacent level fractures

- Reduction in clinically significant AEs
 - BKP compared to SJ system had more than double the rate of ALFs

12.9% v. 27.3% p= 0.043

- Fewer hospital and physician visits
- Decrease in future interventions



Greater pain score reduction

- Less pain medication usage including opioid analgesics at 5 days after surgery (SJ group 7.4% vs. BKP group 21.9%)
- Decreased pain intensity vs. baseline more pronounced in the SJ group at 1 and 6 months

```
1 mo. p= 0.029
6 mo. p= 0.021
```

Mechanical vertebral augmentation Additional SpineJack clinical data

SpineJack data	N-value	Follow-up	Key findings
Bageac, D., & De Leacy, R. * (The Spine Journal 2020) ⁸	27 patients	6 month	 Patients experienced an average vertebral height recovery of 74% Local kyphotic angle was reduced by an average of 50% 33% of patients (n=9) achieved complete restoration of prefracture vertebral height
Crespo-Sanjuán J et al. * (World Neurosurgery 2017) ⁹	178 patients	77 month	 Adjacent fracture rate: 2.2% (4/178 cases) The mean total quantity of cement injected was 4.4 mL The leakage rate was 12.9%, and all of these occurrences were asymptomatic
Noriega D et al. * (Pain Physician 2021) ¹⁰	44 patients	5+ years	 Using SpineJack in the treatment of fractures type A3 is a safe and effective method that allows marked clinical improvement, as well as anatomical vertebral body restoration Results were maintained over time, allowing a better long-term clinical and functional improvement The rate of cement leakage was lower than other reports
Renaud* (Orthopaedics & Traumatology: Surgery & Research 2015) ¹¹	77 patients	35 month	 83 VCFs treated, 51 were due to trauma and 32 to osteoporosis The pain score improvement was 77% at hospital discharge and increased gradually to 86% after 1 year The complication rate is similar to that seen with other vertebral expansion methods, whereas the risk of adjacent fractures is very low
Noriega D et al.* (Turkish Neurosurgery 2016) ¹²	32 patients	12+ month	 52 VCFs treated; 18 patients with metastatic disease, 14 patients with hematologic disease (9 multiple myeloma, 5 lymphoma) Statistically significant improvements in VAS pain and quality of life scores Statistically significant increase in average anterior VB height of 6.2 mm (31.6%) and central VB height of 5.8 mm (34.7%) resulting in significantly reduced kyphotic angle The SpineJack procedure may help reduce the complications associated with vertebral augmentation treatment of malignant VCFs, such as bone cement leakage, adjacent level fractures, and recollapse.

Sacral Insufficiency Fracture







Sacroplasty

- Sacral Insufficiency Fractures
- Known complication of Osteoporosis
- Until recently went untreated or poorly treated
- Newer treatment options have been developed
- Requires very high index of suspicion
- Sacroplasty

Sacral Fracture




Honda Sign









Long Axis




Short Axis



Sacroplasty



Sacroplasty



Conclusion

- Osteoporosis is a significant disease entity
- Diagnosis requires intervention and high level of suspicion
- Treatment is best done through prevention
- IF fracture suspected, recc Imaging and referral for Vertebral Augmentation.

